TY - JOUR JF - Translational Oncology KW - EGFR KW - Liquid biopsy KW - Lung cancer KW - Pleural effusion A1 - Vukovic, Miodrag A1 - Tanic, Miljana A1 - Damjanovic, Ana A1 - Pavlovic, Marijana A1 - Stanojevic, Aleksandra A1 - Zivic, Katarina A1 - Karadzic, Valentina A1 - Jankovic, Radmila A1 - Cavic, Milena ID - discovery10198733 N2 - Background: The use tumor-derived cell-free DNA extracted from body fluids is being evaluated for genetic testing in lung cancer. The aim of this study was to explore the feasibility and utility of implementation of EGFR molecular testing from pleural effusions in non-small cell lung cancer in the clinical diagnostics workflow.// Patients and methods: This study included patients diagnosed with primary lung adenocarcinoma in the period July 2016 to June 2023. EGFR mutation testing was performed by qPCR (Cobas®) and dPCR. Testing was performed from 211 plasma samples when tissue was unavailable at diagnosis, and from 301 plasma samples and 18 pleural effusions at progression on first/second generation of EGFR TKIs. Descriptive methods of statistical analysis were used to summarize the sample data. Fisher's exact test, McNemar's test, Cohen's kappa tests were used for statistical analyses. Two-sided p-values <0.05 were considered statistically significant.// Results: A significantly higher detection rate of the T790M mutation in pleural effusion was obtained compared to blood (50% and 20%, p=0.047). When comparing the detection success rate of the resistant T790M mutation in pleural effusion and blood, a statistically significant difference was obtained in favor of pleural effusion (50% vs. 21.87%, p=0.01).// Conclusions: Superior performance of pleural effusions compared to blood plasma was shown both in the analysis of success rate and in the detection of the resistant T790M mutation, at progression on EGFR TKIs. Pleural effusion should be considered in this setting whenever available, especially in countries with limited health resources. SN - 1936-5233 UR - https://doi.org/10.1016/j.tranon.2023.101772 PB - ELSEVIER SCIENCE INC N1 - © The Author(s), 2023. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CC-BY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ TI - EGFR mutation testing from pleural effusions of non-small cell lung cancer patients at the institute for oncology and radiology of Serbia EP - 8 AV - public Y1 - 2023/11// VL - 37 ER -